| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
In HEK-293 cells, palvanil (0.1-1000 nM; 0-300 minutes) raises intracellular calcium levels [1]. Treatment with palvanil (1–10 nM; 5 min) significantly desensitizes TRPV1 to capsaicin effects [1].
|
|---|---|
| ln Vivo |
A cooling effect has been observed with Palvanil treatment (subcutaneous injection; 1 or 10 mg/kg; once) [2]. The application of palvanil (ip; 100 μL (15 nM) per mouse; once) lessens the constriction of the airways caused by capsaicin [2]. On formalin-induced nociceptive behavior, palvanil (intravenous; 0.5, 0.75, and 1 mg/kg; once) treatment exhibits antinociceptive effects [2]. Carrageenan-induced inflammation is inhibited when Palvanil (IV; 0.5, 0.75, and 1 mg/kg; once) is administered [2]. In mice with nerve injury (SNI), palvanil (intravenous; 0.5 and 1 mg/kg; once daily; 7 days) decreases thermal hyperalgesia and mechanical allodynia [2].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: HEK-293 Cell Tested Concentrations: 0.1, 0.5, 1, 5, 10, 50, 100 and 1000 nM Incubation Duration: 0-300 minutes Experimental Results: Intracellular calcium concentration increased in a dose-dependent manner EC50 is 0.65 nM. Cell viability assay [1] Cell Types: HEK-293-TPRV1 Cell Tested Concentrations: 1-10 nM Incubation Duration: 5 minutes Experimental Results: TRPV1 is Dramatically desensitized to the effect of capsaicin (IC50=0.81 nM). |
| Animal Protocol |
Animal/Disease Models: Male CD-1 mice [2]
Doses: 1 or 10 mg/kg Route of Administration: subcutaneous injection; 1 or 10 mg/kg; primary Experimental Results:causing a mild and short-lived sustained hypothermia effect, producing late hyperthermia. Animal/Disease Models: Female balb/c (Bagg ALBino) mouse [2] Doses: 100 μL (15 nM) per mouse Route of Administration: intraperitoneal (ip) injection; 100 μL (15 nM) per mouse; Experimental Results:Dramatically diminished bronchoconstriction ( from 0.47 to 0.605 cm H2O/L/s). Animal/Disease Models: Male CD-1 mice received formalin [2] Doses: 0.5, 0.75 and 1 mg/kg Route of Administration: intravenous (iv) (iv)injection; 0.5, 0.75 and 1 mg/kg; Experimental Results: In a dose-dependent manner The second phase of reducing formalin-induced nociceptive behavior. Animal/Disease Models: Carrageenan-induced acute inflammation in male C57BL/6J mice [2] Doses: 2.5 mg/kg Route of Administration: intravenous (iv) (iv)injection; 2.5 mg/kg; one-time Experimental Results:ipsilateral hind paw edema volume diminished (64% ). Animal/Disease Models: Male CD-1 mice [2] Doses: 0.5 and 1 mg/kg Administratio |
| References |
|
| Molecular Formula |
C24H41NO3
|
|---|---|
| Molecular Weight |
391.58724
|
| Exact Mass |
391.309
|
| CAS # |
69693-13-6
|
| PubChem CID |
9952407
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.338
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
28
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
|
| InChi Key |
SGEUEXJZQFSBNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H41NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-24(27)25-20-21-17-18-22(26)23(19-21)28-2/h17-19,26H,3-16,20H2,1-2H3,(H,25,27)
|
| Chemical Name |
N-[(4-hydroxy-3-methoxyphenyl)methyl]hexadecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5537 mL | 12.7685 mL | 25.5369 mL | |
| 5 mM | 0.5107 mL | 2.5537 mL | 5.1074 mL | |
| 10 mM | 0.2554 mL | 1.2768 mL | 2.5537 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
